With Feasibility Study Completed, ICC Begins Construction of Danish Facility


Tony Deyes

July 2nd, 2019

App, Exclusive, News, Top News


Breaking with the traditionally-strict policies of the Scandinavian region on January 1, 2018, Denmark legalized medical cannabis through a unanimous vote by parliament, and Denmark is now poised to become one of Europe’s top producers of medical-grade cannabis.

International Cannabis Corp. (CSE: WRLD, OTC: KNHBF) has already built an impressive European footprint, and plans to further expand its Danish presence with the construction of a 150,000 square foot GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility, situated on a 100-acre land parcel in Møldrup, Denmark.

Denmark an Ideal Hub

Aside from the considerable support the Danish government has given to the cannabis industry, the country is attractive to producers because of its access to skilled manufacturing and agricultural labour, especially its plant breeding and genetics expertise, an ample supply of inexpensive, increasingly-clean power, and no cap or quotas on medical cannabis production. The country also has a well-financed healthcare system that is cannabis-friendly and an established pharmacy network for distribution.

Its proximity to larger import-based markets such as Germany and the broader EU makes it an excellent entry point into the European market. With a population twice the size of the US and Canada combined, and a cannabis industry still in its infancy compared to North America’s, currently experiencing supply shortages, Europe offers an enormous opportunity.

Expanding Capacity

The company engaged a leading Denmark based international pharma engineering firm to perform a comprehensive feasibility study on the Danish facility, which found that once fully operational, it should achieve annualized production capabilities of around 20,000 kg. of artisanal grown, ultra-premium dried cannabis flower for sale into high-value medical markets.

Leveraging proprietary design and build IP, as well as its proven cultivation methodologies, ICC seeks to optimize each square foot, and achieve further efficiencies by way of customized process design and building systems. Capacity simulation scenarios will further refine cost estimations while optimizing production, processing, manufacturing, and distribution work flows.

ICC CEO David Shpilt said, “Through highly coveted and stabilized genetics, state of the art building control systems to achieve pharmaceutical standardization of medical cannabis, and a proprietary Quality Management System, ICC’s Danish production facility will yield the finest cannabis products to meet the demands of educated, sophisticated and quality-driven consumers.”

The standalone, single level 150,000 square foot facility will be constructed in four portioned blocks, leveraging modular designs that are intended to streamline future expansion.

The cultivation block will include 56,250 sq. ft. of net flower canopy designed for five annual harvests, as well as 55,00 sq. ft. of dedicated production space including 20,400 sq. ft. of processing infrastructure with additional packaging and distribution capabilities.

20,000 sq. ft. will be set aside for administration office, gowning and utilities, a GMP-compliant waste disposal area, segregated GDP loading bays, proprietary building management, facility monitoring, and quality management systems, and apportioned GACP and EU-GMP areas, including air locked access corridors.

Shplit added, “The completion of our 150,000 Danish Facility on time and within budget, will signal to the marketplace that ICC has established yet another flagship cultivation and manufacturing hub; enabling the distribution of high-margin products into high-value European patient populations with drastically shorter lead times. Through astute engineering and planning, our industry leading facility will be constructed in independent purpose-built blocks, supporting expansion of capacity and new functions while maintaining full operational capabilities.”

Maximizing Yields

In order to optimize plant performance to achieve greater yields, ICC will leverage numerous plant physiology and cultivation concepts developed through its five years of commercial cultivation experience in Canada, such as proprietary soil, nutrient, and plant health monitoring, consistent primary, secondary, and micro nutrient delivery, the manipulation of conditions driving plant health & yield, and the creation of crops with increased pest/disease resistance.

International Cannabis also plans to pursue the outdoor cultivation of high quality, low cost field crops on 45 acres of farmable land, as soil sampling of the Danish land package has indicated ideal soil composition and health. With increased organic matter levels as a result of implementing its outdoor agricultural program, ICC is forecasted to yield 81,000 kg dried cannabis in the 2020 harvest season from its of auto-flower and photoperiod cannabis crops.

These developments are only one chapter in the evolving ICC story. The company, through its subsidiaries, has agreements in place for European-based pharmaceutical distribution, wholesale importation, and research and development, as well as licenses to cultivate, produce, distribute, store and export cannabis, cannabis derivatives and industrial hemp in  Poland, Greece, Portugal, Colombia, South Africa and the Kingdom of Lesotho.

With an established presence on five continents, 110 clients representing roughly 3500 pharmacies in 16 countries, five licenses for cultivation on three continents and access to over 850 acres of premium hemp crops (estimated to produce up to 6800 tons of biomass for CBD extraction), International Cannabis is well on it way to creating the first truly global cannabis supply chain.

For more of the ICC story, please visit https://intlcannabiscorp.com/

And connect with them on social media:

https://www.facebook.com/ICCWRLD/

https://twitter.com/ICC_WRLD

https://www.linkedin.com/company/icc-wrld/

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Avatar

About Tony Deyes



Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading